The biopharmaceutical manufacturing landscape is undergoing a profound transformation.
As the industry pivots toward advanced injectable therapies and next-generation biologics, the convergence of scientific innovation, evolving patient needs and regulatory scrutiny is reshaping supply chains.
Anthony Vico (pictured), Head of US Technology Excellence Center at Stevanato Group, takes up the story.
Injectable innovation drives supply chain complexity
The rapid growth of monoclonal antibodies and the surging demand for GLP-1 receptor agonists are accelerating the shift toward subcutaneous administration and large-volume injectables for at-home use.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.